Day Case Lumbar Fusion Surgery
The article discusses a retrospective cohort study comparing the clinical efficacy of minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) and open transforaminal lumbar interbody fusion (OPEN-TLIF) in the treatment of II° lumbar isthmic spondylolisthesis (IS). The study examined 101 patients with II° lumbar IS who underwent surgical treatment, with 53 receiving MIS-TLIF surgery and 48 receiving OPEN-TLIF surgery. The study found that MIS-TLIF resulted in lower amounts of intraoperative blood loss, postoperative drainage, and postoperative hospital stay compared to OPEN-TLIF. The MIS-TLIF group also had lower complication rates and better low back pain relief. However, there were no significant differences in postoperative leg pain score, slippage rate, and fusion rate between the two groups. Overall, the study suggests that MIS-TLIF has advantages in terms of pain relief, trauma, and recovery and is worthy of clinical promotion
Summarised by Mr Mo Akmal – Lead Spinal Surgeon
The London Spine Unit : most specialised day surgery spinal centre in London
Published article
Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) is not suitable for high-grade isthmic spondylolisthesis, whether MIS-TLIF can treat II° lumbar isthmic spondylolisthesis (IS) is still controversial. This retrospective cohort study compared the clinical efficacy of MIS-TLIF and open transforaminal lumbar interbody fusion (OPEN-TLIF) in the treatment of II° lumbar IS. From January 2017 to January 2023, 101 patients with II° lumbar IS were diagnosed in our hospital and…
Lumbar Fusion Surgery Expert. Best Spinal Surgeon UK
Medicine (Baltimore). 2023 Oct 6;102(40):e35420. doi: 10.1097/MD.0000000000035420.ABSTRACTMinimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) is not suitable for high-grade isthmic spondylolisthesis, whether MIS-TLIF can treat II° lumbar isthmic spondylolisthesis (IS) is still controversial. This retrospective cohort study compared the clinical efficacy of MIS-TLIF and open transforaminal lumbar interbody fusion (OPEN-TLIF) in the treatment of II° lumbar,
Medicine (Baltimore). 2023 Oct 6;102(40):e35420. doi: 10.1097/MD.0000000000035420.
ABSTRACT
Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) is not suitable for high-grade isthmic spondylolisthesis, whether MIS-TLIF can treat II° lumbar isthmic spondylolisthesis (IS) is still controversial. This retrospective cohort study compared the clinical efficacy of MIS-TLIF and open transforaminal lumbar interbody fusion (OPEN-TLIF) in the treatment of II° lumbar IS. From January 2017 to January 2023, 101 patients with II° lumbar IS were diagnosed in our hospital and underwent surgical treatment, of which 53 received MIS-TLIF surgery and 48 received OPEN-TLIF surgery. The operation time, blood loss and surgical complications were compared between the 2 groups. The pain, function, reduction rate and fusion rate of the patients were evaluated during follow-up. The amount of intraoperative blood loss, postoperative drainage, and postoperative hospital stay in the MIS-TLIF group were significantly lower than those in the OPEN-TLIF group were (P < .01). In the MIS-TLIF group, there were 1 case of dural sac injury and 3 cases of lower limb paralysis. The complication rate of MIS-TLIF was lower than the OPEN-TLIF group (P = .032). In the visual analog scale score of low back pain, the MIS-TLIF group was lower than the OPEN-TLIF group after operation and at the last follow-up. There were no significant differences in postoperative leg pain score, slippage rate, and fusion rate between the 2 groups. Compared with OPEN-TLIF, MIS-TLIF has the advantages of better low back pain relief, less trauma, less bleeding and faster recovery, and is worthy of clinical promotion.
PMID:37800840 | DOI:10.1097/MD.0000000000035420
The London Spine Unit : most specialised day surgery spinal centre in London
Read the original publication:
Clinical efficacy of minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) in the treatment of II° lumbar isthmic spondylolisthesis: A retrospective cohort study
